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Objective: plasmin is a common activator of the known proteolytic systems involved in the aneurysmal degradation, and is
reported to be associated with the expansion of abdominal aortic aneurysms (AAA). The aim of this study was to study the
activating pathways of plasminogen as predictors of the progression of AAA.
Materials and Methods: one hundred and twelve of 122 male patients with a small AAA (def.:  3 cm) were interviewed,
examined, had blood samples taken at diagnosis, and scanned annually for 1±5 years (mean 3.5 years), and referred for
surgery if the AAA exceeded 5 cm in diameter.
A random sample of 70 of the 112 cases had plasma levels of urokinase-like-plasminogen activator (uPA), tissue-
type±plasminogen activator (tPA), plasminogen-activator-inhibitor-1 (PAI-1), macrophage inhibiting factor (MIF),
tumour-growth-factor-b1 (TGF-b1), homocysteine, and serum levels of IgA-antibodies against Chlamydia pneumoniae
(IgA±CP) and Cotinine (a nicotine metabolite) measured. Spearmans correlation analysis was used for statistics.
Results: the annual expansion rate correlated positively with tPA, IgA±CP and S-Cotinine; r 0.37 (p 0.002), 0.29
(p 0.006) and 0.24 (p 0.038), while PAI1, uPA, TGF-b1, homocysteine, and MIF did not. S-Cotinine did also correlate
positively with tPA, r 0.24 (p 0.049).
Conclusion: the aortic matrix degradation in AAA may be partly caused by an activation of plasminogen by tPA, but
apparently not by uPA, which usually dominates matrix degradation. Smoking seems to be a factor for this pathway, while
the pathways of IgA±CP and MIF, a new marker of aneurysmal progression, seem different. The latter observations suggest
that other proteolytic pathways are involved in the aortic wall degradation in AAA.
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Introduction
The identification of predictors of the expansion of
small abdominal aortic aneurysms (AAA) may
become important for managing this type of patients
with regard to operative intervention or other thera-
pies, and may also help to understand the patho-
genesis of AAA.
Three proteolytic systems seem to be involved in
the degradation of aorta causing AAA;
1. The serine-dependent proteases. The levels of elastase
have been found elevated in circulation and aneur-
ysmal walls compared with aortic walls of occlu-
sive atherosclerosis.1±3
2. The cysteine-dependent proteases. Circulating levels of
Cystatin C ± the major inhibitor of cysteine
proteases ± have been reported decreased in aneur-
ysmal cases compared with a sex- and age-matched
control group,4 and negatively correlated to aneur-
ysmal expansion rate.5
3. The metallodependent proteases. Levels of various
metallodependent proteases especially MMP2 and
MMP9 have been found elevated in aneurysmal
aortic walls compared with aortic walls of occlusive
atherosclerosis.6,7 The plasma level of MMP9 has
also been correlated with the expansion of small
AAA.8
Besides its fibrinolytic function in plasma, plasmin
also plays a central role in the activation of the degen-
erative processes in tissues. Thus, plasmin is a common
activator of the mentioned proteolytic systems,9±11 and
could be involved in the pathogenesis of AAA.
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Recently, we demonstrated the plasma concentrations
of plasmin±antiplasmin complex (PAP) correlates
with aneurysmal expansion and are predictive for
cases expanding to operation recommendable sizes
in a cohort of male AAA-patients diagnosed by ultra-
sonographic screening.12 Years ago, Reilly et al.
claimed that uPA and especially tPA is expressed
more in AAA than in atherosclerotic occlusive
aortae.13 Consequently, this study was performed in
order to study potential prognostic markers for aortic
expansion in this plasmin activation. As potential acti-
vators of tPA or uPA, smoking, homocysteine, IgA±
CP, MIF, and TGF-b1 were also studied.
Material and Methods
In 1994, half (4404) of all 65±73 year-old males in
Viborg County, Denmark, were invited to B-mode-
ultrasonographic screening for AAA at their regional
hospital.14 An AAA was defined as an aortic diameter
of 30 mm or more. The participants were informed,
interviewed, and examined, including a rescan, by the
trial doctor. An AAA was defined as an infrarenal
aortic diameter of 30 mm or more, and AAA
450 mm were referred for surgery. AAA of 30±
49 mm was offered yearly follow-up examinations to
check for any expansion.
The expansion was calculated as the change in the
anterior±posterior (AP) diameter during the whole
observation period, transformed to annual units.
All the patients with an AAA consulted the trial
doctor for information, examination, and a rescan.
Two observers were used. Their arimetric inter-
observer variation (2s.d.) of the measurements was
1.4 mm.14
In order to reduce the round the clock variations of
the various serological parameters, all samples were
taken between 9.00 a.m. and 12.00 noon by the screen-
ing team.15 It was impossible to do this during the
daily screening sessions, so sample days were
arranged within ten days of the initial scan. Only
subjects living less than 30 km from the hospital were
asked to attend blood sampling, and two of these
refused sampling. In all, 13 had no blood samples
taken. Their age, AAA size, and systemic blood pres-
sures did not differ from those who had blood sam-
ples taken. The plasma samples were stabilized with
EDTA and left at 18 C in 45 min before centrifugation.
Hereafter serum and plasma samples were stored in
multiple aliquots at ÿ 70 C until analysis. Due to lim-
ited economical resources, a random sample had
plasma levels of urokinase-like-plasminogen activator
(uPA), tissue-type-plasminogen activator (tPA),
plasminogen-activator-inhibitor-1 (PAI-1), macro-
phage inhibiting factor (MIF), tumour-growth-factor-b1
(TGF-b1), homocysteine, and serum levels of IgA-
antibodies against Chlamydia pneumoniae (IgA±CP)
and Cotinine (a nicotine metabolite) measured. All
parameters were measured in all patients.
The randomization was performed with the utility
in EPI-info 6. P-PAI-1 was measured with the ELISA
`` Imulyse PAI-1'' from Biopool Int., UmeaÊ, Sweden.
The within- and between-assay coefficient of variation
is 5 and 9%, respectively. It detects latent and active
PAI-1, but poorly complexes with uPA and tPA.16
Similarly, the P-tPA was measured with the ELISA
`` Imulyse tPA'' from Biopool Int., UmeaÊ. The within-
and between-assay coefficient of variation is 8 and
10%, respectively. It detects free single and two-chain
tPA and tPA in complex with its inhibitors.17
P-uPA was measured with the ELISA `` Imulyse
uPA'' from Biopool Int., UmeaÊ. The within- and
between-assay coefficient of variation is 5 and 9%,
respectively. It detects free single and two-chain uPA
and uPA in complex with its inhibitors.18
MIF levels in serum were measured blindly with a
routine MIF-specific sandwich ELISA using recombin-
ant human MIF as standard.19,20 The coefficient of
variation was 18.5%.
Serum TGF-b1 levels were determined using
TGF-b1 ELISA kit according to the manufacturer
(BioSource International, Camarillo, CA). The coeffi-
cient of variation was 28%.
P-total homocysteine (P-tHcy) were analysed using
gas chromatography-mass spectrometry after reduc-
tion with dithiothreitole. Deuterated homocysteine
was used as internal standard.21 The inter- and intra-
assay coefficient of variation of the P-tHcy measure-
ments was 5 and 3%, respectively, as assessed by
internal and external quality assessment.21
IgA antibodies against C. pneumoniae measured by
means of microimmunoflourescence (MIF) tests.22
S-Cotinine were determined by a commercial radio-
immunoassay (Diagnostic Products Corp., LA, U.S.A.)
modified as suggested by Perkins et al.23 The analy-
tical coefficient of variation was 5.4%. The trial was
approved by the national board of health, local scien-
tific ethics committee and reported to the data protec-
tion authorities.
Wilcoxons non-parametric test for unpaired data
was used to compare selected and non-selected cases
from the population. Spearmann's correlation anal-
yses were used to correlate the parameters initially
with expansion rate, and secondary, significant find-
ings with tPA and uPA. To correct for the possibility
of chance findings, the p-values in primary and
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secondary correlations were multiplied with the num-
ber of tests performed, respectively.
Finally, logarithmic transformation of S-Cotinine
were performed in order to make a multiple regres-
sion analysis concerning tPA and expansion rate
adjusting for smoking.
Results
Of the 4404 men invited to screening, 3344 (76%)
attended, and an AAA was diagnosed in 141 of these
(4.2%). Nineteen AAA were over 5 cm in diameter,
and these patients were soon referred for surgery;
the remaining 122 cases were offered annual control
scans and referred for surgery if the AAA expanded to
more than 5 cm in diameter. Ten cases were lost to
follow up due to death or severe illness during the
first year, and the rest have been followed for one to
five years, in average 3.5 years.
The medians and interquartiles of the parameters
among the selected and non-selected cases from the
population are shown in Table 1. There were no differ-
ences between the selected and non-selected cases
concerning age, initial AAA diameter, systolic
and diastolic blood pressure, and mean annual expan-
sion rate.
The annual expansion rate correlated positively
with tPA, IgA±CP and S-Cotinine; r 0.37 (p 0.002,
Fig. 1), 0.29 (p 0.006) and 0.23 (p 0.038), while
MIF (r 0.22, p 0.061), PAI-1 (r 0.015, p 0.015),
uPA (r 0.001, p 0.993, Fig. 2), TGF-b1 (r 0.001,
p 0.999), and Homocysteine (r 0.063, p 0.535)
did not. Adjustment for the risk of chance findings
removed the significant finding of S-Cotinine, while
tPA and IgA±CP were still significantly associated
with expansion rate.
S-Cotinine did also correlate positively with tPA,
r 0.24 (p 0.049) negatively significantly with uPA
(r ÿ 0.345, p 0.006), while IgA±CP did not correlate
with tPA or uPA (Table 2). Logarithmic transformation
of S-Cotinine and tPA normalised their distributions
acceptable. In multiple linear regression analyses
adjusting for S-Cotinine, the correlation between tPA
and expansion rate remained significantly correlated,
while S-Cotinine failed to reach significance and
vice versa if the sequence of independent variables
was reversed.
Discussion
The study showed significantly positive correlations
between tPA, S-Cotinine, and aneurysmal progression
but not with uPA, which usually dominates matrix
degradation. The latter may be due to the fact that
the binding of uPA to their specific receptors on the
membrane of the cells is quite stable and long lasting
in order to cause local matrix degradation. It may
prevent inactivation but maybe also relevant for sys-
temic detection. This mechanism and the unavoidable
pollution of the systemic measurement of uPA origi-
nating from non-aortic locations, could explain the
missing correlation with aneurysmal expansion.
The optimal study design would of cause have been
also to have aortic samples tested, but this was obvi-
ously not possible in this prospective study. Neverthe-
less, the present study shows that systemic
measurement of uPA is not prognostic for the progres-
sion of AAA.
Table 1. Medians and interquartiles of the various analysed parameters compared with the non-selected part of the population of
screening diagnosed small abdominal aortic aneurysms. p-values from a non-parametric comparison of these two subgroups are shown
in the right column.
Selected population
(n 70)
Non-selected population
(n 52)
p-value
25th Quartiles Median 75th Quartiles 25th Quartiles Median 75th Quartiles
Age (years) 65 67 70 66 68 70 0.23
Diastolic BP (mmHg) 80 90 100 85 90 100 0.84
AAA-size (mm) 31 33 38 30 32 36 0.48
Expansion rate (mm/year) 0.92 2.61 3.89 0.74 2.39 3.87 0.83
tPA (ng/ml) 6.80 9.70 13.2
PAI-1 (ng/ml) 22.5 31.3 40.0
uPA (ng/ml) 1.53 1.80 2.40
IGA±CP (ie/l) 10 19 29
Homocysteine (mmol/l) 11.8 14.2 18.0
MIF (ng/ml) 0.00 2.30 3.85
TGF-b1 (ng/ml) 445 527 598
Cotinine (ng/ml) 0.00 165 340
n 42 concerning expansion data.
548 J. S. Lindholt et al.
Eur J Vasc Endovasc Surg Vol 25, June 2003
They also did an immunohistochemistry study,
which showed that tPA in normal aortas only are
present in the intima, while tPA is diffusely present
in the intima and media of AAA-walls. UPA was only
present in the monocellular cells in the infiltrate asso-
ciated with the adventitia13 in AAA-walls. Thus the
role of uPA in AAA remains unsolved. The described
localization in the adventia13 could indicate a role
in the neo-angiogenesis as suggested by Scheiderman
et al.27
TPA is binding to the surface of the matrix in order
to cause matrix degradation and avoid inactivation
from PAI. The inactivation is very strong and fast
when tPA leaves their receptors. However, in spite of
this and the potential pollution with tPA from non-
aortic locations, a strong correlation between tPA and
aneurysmal expansion rate was noticed indicating
that the cell and matrix plasmin activation through
the tPA pathway could play a major role in the pro-
gression of small AAA. One could argue, that the
events going on in the AAA wall probably has nothing
or very little to do with the systemic changes as we
were measuring. However, AAA is associated with
structural changes in the other parts of the major and
even minor arterial vessels24,25 without any sign of
dilatation yet. These laboratory reports are comple-
mentary to the clinical knowledge that AAA is asso-
ciated with arterial dilatations and aneurysms at other
locations. Thus, we may be able to demonstrate the
association between arterial wall degradation and
tPA, otherwise the role of tPA in the AAA is so strong
that it overcomes the pollution of tPA from other
locations. The design of this present study can never
discriminate between these two possibilities.
Again, the optimal study design would of cause
have been also to have aortic samples tested. Never-
theless, the present study shows that systemic meas-
urement of tPA may have a potential of being a
clinically useful prognostic marker. However, a larger
sample size, longer follow up time, and perhaps
repeated measurements are needed before any clinical
recommendations can be made.
In all, we believe this prospective study supports
Reillys suggestion, that plasminogen activators par-
ticipate in the pathogenesis of AAA, and that this
participation is unique because it is mainly performed
by tPA.
Genetic polymorfic variations in PAI-1 have been
associated with family AAA.26 However, it did
not correlate with the expansion rate suggesting a
minor, if any role, in the progression of AAA.
Smoking28±30 and hyperhomocysteineamia31 has
been associated with AAA, and is known to influence
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Fig. 2. Scatter plot of the correlation between P-uPA and the annual
expansion rate of small abdominal aortic aneurysms. Spearmann's
r 0.001 (p 0.993).
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Fig. 1. Scatter plot of the correlation between P-tPA and the annual
expansion rate of small abdominal aortic aneurysms. Spearmann's
r 0.37 (p 0.002).
Table 2. Non-parametric correlation matrix between activators and
inhibitors of plasminogen, and the size and progression of small
abdominal aortic aneurysms. Spearmann's correlation coeffi-
cients, p-values in parenthesis.
tPA uPA Cotinine IgA±CP
Expansion rate
(mm/yr)
0.368
(0.002)
0.001
(0.993)
0.234
(0.038)
0.290
(0.006)
tPA (ng/ml) 0.125
(0.308)
0.238
(0.049)
0.135
(0.252)
uPA (ng/ml) ÿ0.345
0.006
ÿ0.053
0.690
 p5 0.05.
** p5 0.05 after correction for mass significance.
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relevant matrix proteases. TGF-b1,32 MIF33 and IgA±
CP34 are also reported associated with AAA but their
pathway is partly unknown. Consequently, they were
studied in order to be potential activators of tPA
or uPA.
The positive correlations between S-Cotinine, tPA
and expansion rate suggests that smoking is partici-
pating in this pathway, and smoking has been
reported associated with AAA and aneurysmal
progression.28±30
This is in accordance with the confounding which
seemed to be present in the performed multiple linear
regression analyses since the significant correlations
between expansion rate, tPa and S-Cotinine, tPA
disappeared. However, the association between
S-Cotinine and expansion rate was relatively weak,
and failed to reach significance when adjusted for
the risk of chance findings.
The lack of significant correlations between tPA,
IgA±CP and MIF, two other markers of aneurysmal
progression,33,34 suggests additional proteolytic
pathways must be involved. MIF levels did not
correlate with expansion rate (p 0.06). However, it
was recently reported to correlate positively with
aneurysmal expansion.35,36 The negative result in this
study may be due to the relatively low numbers
studied, a relatively high frequency of cases with
MIF-levels below the detection border and a relatively
high CV.
TGF-b1 is suspected to activate tPA and PAI-110 but
it did not correlate with expansion rate. However, the
high variation of the measurements of TGF-b1, the
interobserver variation of the aortic measurements,
and the pollution of TGF-b1 originating from non-
aortic locations could hide a weak correlation.
The role of hyperhomocysteinaemia in atheroscler-
osis and AAA remains controversial; it has been
reported increased in AAA cases in a case-control
study,31 and is known to influence the matrix pro-
teases.36 Consequently, we analysed it in this study,
but could not find any trends in association with
aneurysmal expansion rate.
Other known factors of importance for the acti-
vation of tPA and uPA as endothelium growth factor
(EGF), platelet-derived growth factor (PDGF), inter-
leukin 1, gamma-interferon, and tumour necrosis
factor (TNF)10 were not examined due to limited
resources.
Conclusion
Aneurysmal progression may be partly caused by an
activation of plasminogen by tPA, and probably not by
uPA, which usually dominates matrix degradation.
Smoking seems to influence this pathway, while the
pathways of IgA±CP and MIF, a new marker of aneur-
ysmal progression, seem different. The latter observa-
tions suggest that other proteolytic pathways are
involved in the aortic wall degradation in AAA.
Systemic measurement of tPA may become a clinic-
ally useful prognostic marker of aneurysmal progres-
sion. However, a larger sample size, longer follow up
time, and perhaps repeated measurements are needed
before any clinical recommendations can be made.
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